SEC Company Response from Axovant Gene Therapies Ltd. (CIK 0001636050) — Jun 11, 2020
Axovant Gene Therapies Ltd. (CIK 0001636050)
Date: June 11, 2020 · CIK: 0001636050 · Accession: 0001104659-20-072458
AI Filing Summary & Sentiment
File numbers found in text: 333-235889
Letter
June 11, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Paul Fischer
Re:
Axovant Gene Therapies Ltd.
Registration Statement on Form S-3
File No. 333-235889
Acceleration Request
Requested Date:
Monday, June 15, 2020
Requested Time:
4:00 P.M. Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-235889) (the “Registration Statement”) to become effective on June 15, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Milson Yu at (650) 843-5296.
[Signature page follows]
Very truly yours,
Axovant Gene Therapies Ltd.
Show Raw Text
CORRESP 1 filename1.htm June 11, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer Re: Axovant Gene Therapies Ltd. Registration Statement on Form S-3 File No. 333-235889 Acceleration Request Requested Date: Monday, June 15, 2020 Requested Time: 4:00 P.M. Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-235889) (the “Registration Statement”) to become effective on June 15, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Milson Yu at (650) 843-5296. [Signature page follows] Very truly yours, Axovant Gene Therapies Ltd. By: /s/ David Nassif David Nassif Principal Financial Officer cc: Pavan Cheruvu, Axovant Gene Therapies Ltd. John McKenna, Cooley LLP Milson Yu, Cooley LLP